Show simple item record

dc.contributor.authorWilliams, DM
dc.contributor.authorHobson, R
dc.contributor.authorImeson, J
dc.contributor.authorGerrard, M
dc.contributor.authorMcCarthy, K
dc.contributor.authorPinkerton, CR
dc.contributor.authorStud, UKCC
dc.date.accessioned2018-09-18T10:36:38Z
dc.date.issued2002-06
dc.identifier4
dc.identifier.citationBRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 pp. 812 - 820
dc.identifier.issn0007-1048
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2770
dc.identifier.doi10.1046/j.1365-2141.2002.03482.x
dc.description.abstractFrom June 1990 to June 1998, 72 patients with anaplastic large cell lymphoma (ALCL) were treated with short intensive multi-agent regimens [non-Hodgkin’s lymphoma (NHL) 9000 and 9602]. Diagnosis was based on morphological and immunophenotypic criteria. Treatment for stage I disease consisted of eight courses (2 x vincristine, doxorubicin, prednisolone; 2 x methotrexate; 2 x cytarabine, thioguanine; and 2 x methotrexate etoposide). For stage II, III and non-central nervous system (CNS) stage IV, two COPADM (cyclophosphamide, doxorubicin, prednisolone, methotrexate, vincristine), two CYM (cytarabine methotrexate) and a COPADM was given. For CNS-positive disease, treatment was intensified and contained methotrexate 8 g/m(2) and cytarabine 3 g/m(2) . Fifty-nine patients (82%) achieved a remission. Thirteen of these relapsed, with a median time to relapse from the start of treatment of 5 months (range 3-14). Relapse included a new site in 9/13 patients. The probabilities of overall and event free survival at 5 years were 65% (53-76%) and 59% (47-70%), respectively, with a median follow up of 4.3 years. Mediastinal and visceral involvement at presentation were found to be predictive of an increased risk of failure.
dc.format.extent812 - 820
dc.languageeng
dc.language.isoeng
dc.titleAnaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens
dc.typeJournal Article
rioxxterms.versionofrecord10.1046/j.1365-2141.2002.03482.x
rioxxterms.licenseref.startdate2002-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBRITISH JOURNAL OF HAEMATOLOGY
pubs.notesresearcherid-numbers: pinkerton, ross/I-4808-2014 unique-id: ISI:000176130100006
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume117
pubs.embargo.termsNot known
dc.contributor.icrauthorPinkerton, Rossen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record